A spatial simulation approach to account for protein structure when identifying non-random somatic mutations

BMC Bioinformatics

Volumn 15, Issue 1, 2014, Pages

  Ryslik, Gregory A ^a   Cheng, Yuwei ^a   Cheung, Kei Hoi ^a,b   Bjornson, Robert D ^c   Zelterman, Daniel ^a   Modis, Yorgo ^a   Zhao, Hongyu ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; AMINO ACIDS; BIOINFORMATICS; DISEASES;

CLUSTER IDENTIFICATION ALGORITHMS; NOVEL METHODOLOGY; PROTEIN DATA BANK; PROTEIN STRUCTURES; PROTEIN TERTIARY STRUCTURES; SOMATIC MUTATION; SPATIAL INFORMATIONS; SPATIAL SIMULATION;

PROTEINS;

PROTEIN;

ALGORITHM; ARTICLE; BIOLOGY; CHEMISTRY; CLUSTER ANALYSIS; GENETICS; HUMAN; METHODOLOGY; MUTATION; NEOPLASM; PROTEIN DATABASE; PROTEIN TERTIARY STRUCTURE; TUMOR GENE;

ALGORITHMS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; GENES, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTEINS;

EID: 84907736990     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-231     Document Type: Article

References (57)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10(8):789-799. [http://www.ncbi.nlm.nih.gov/pubmed/15286780]. [PMID: 15286780].
2. Faivre S, Kroemer G, Raymond E. Current development of mTOR, inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5(8):671-688. [http://www.nature.com/doifinder/10.1038/nrd2062].
3. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009, 10(5):470-481. [PMID:, 1968 9244].
4. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120(5):947-959. [http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-04-403733].
5. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, , et al. O'Meara S Patterns of somatic mutation in human cancer genomes. Nature 2007, 446(7132):153-158. [http://www.nature.com/doifinder/10.1038/nature05610]
6. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Prac Oncol 2006, 3(8):448-457. [http://www.ncbi.nlm.nih.gov/pubmed/16894390]. [PMID: 16894390].
7. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JKV, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, . Leary RJ The consensus coding sequences of human breast and colorectal cancers. Science (New York NY) 2006, 314(5797):268-274. [PMID: 16959974], Leary RJ.
8. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JKV, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine kinome in colorectal cancers. Science (New, York, N.Y.) 2003, 300(5621):949. [http://www.ncbi.nlm.nih.gov/pubmed/12738854]. [PMID: 12738854].
9. Wang T. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Nat Acad Sci 2002, 99(5):3076-3080. [http://www.pnas.org/cgi/doi/10.1073/pnas.261714699].
10. Youn A, Simon R. Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics 2010, 27(2):175-181. [http://bioinformatics.oxfordjournals.org/cgi/doi/10.1093/bioinformatics/btq630].
11. Kreitman M. Methods to detect selection in populations with applications to the human. Ann Rev Genom Hum Genet 2000, 1:539-559. [http://www.annualreviews.org/doi/abs/10.1146/annurev.genom.1.1.539].
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004, 350(21):2129-2139. [PMID: 15118073].
13. Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer Res 2008, 68(6):1675-1682. [http://www.ncbi.nlm.nih.gov/pubmed/18339846]. [PMID: 18339846].
14. Wagner A. Rapid detection of positive selection in genes and genomes through variation clusters. Genetics 2007, 176(4):2451-2463. [http://www.genetics.org/cgi/doi/10.1534/genetics.107.074732].
15. Zhou T, Enyeart PJ, Wilke CO. Detecting clusters of mutations. PLoS, ONE 2008, 3(11):e3765. [http://dx.plos.org/10.1371/journal.pone.0003765].
16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7(4):248-249. [http://www.nature.com/doifinder/10.1038/nmeth0410-248].
17. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009, 69(16):6660-6667. [http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-09-1133].
18. Breiman L. Random forests. Mach Learn 2001, 45:5-32. [doi:10.1023/A].
19. Friedman N, Geiger D, Goldszmidt M. Bayesian network classifiers. Mach Learn 1997, 29(2-3):131-163.
20. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995, 20(3):273-297. [http://www.springerlink.com/index/10.1007/BF00994018].
21. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011, 39(17):e118-e118. [http://www.nar.oxfordjournals.org/cgi/doi/10.1093/nar/gkr407].
22. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001, 11(5):863-874. [PMID: 11337480].
23. Ye J, Pavlicek A, Lunney EA, Rejto PA, Teng C. Statistical method on nonrandom clustering with application to somatic mutations in cancer. BMC Bioinformatics 2010, 11:[http://www.biomedcentral.com/1471-2105/11/11].
24. Ryslik G, Cheng Y, Modis Y, . Cheung kH Utilizing protein structure to identify non-random somatic mutations. pre-print 2013, [ArXiv:1302.6977 [q-bio.GN]], Cheung kH.
25. Ryslik GA, Cheng Y, Cheung KH, Modis Y, . Zhao H A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. pre-print 2013, [ArXiv:1303.5889], Zhao H.
26. Borg I, Groenen PJF. Modern multidimensional scaling : theory and applications 1997, New York: Springer.
27. Consortium TU. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2011, 40(D1):D71-D75. [http://www.nar.oxfordjournals.org/cgi/doi/10.1093/nar/gkr981].
28. Pages H, Aboyoun P, Gentleman R, . DebRoy S Biostrings: String objects representing biological sequences, and matching algorithms. 2012, [R package version 2.24.1], DebRoy S.
29. Gong Y, Kakihara Y, Krogan N, Greenblatt J, Emili A, Zhang Z, Houry WA. An atlas of chaperone-protein interactions in Saccharomyces cerevisiae: implications to protein folding pathways in the cell. Mol Syst Biol 2009, 5. [http://www.nature.com/doifinder/10.1038/msb.2009.26].
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological) 1995, 57:289-300. [http://www.jstor.org/stable/2346101].
31. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999, 18(27):4044-4046. [PMID: 10435629].
32. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999, 59(2):269-273. [PMID: 9927029].
33. Siraj A, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, Radu A, Ghinea N. Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. BMC, Cancer 2013, 13:246. [http://www.biomedcentral.com/1471-2407/13/246].
34. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, Haga T, Kobayashi T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482(7386):547-551. [http://www.nature.com/doifinder/10.1038/nature10753]. [PDB ID: 3UON].
35. Ockenga W, Kühne S, Bocksberger S, Banning A, Tikkanen R. Non-neuronal functions of the M2 muscarinic acetylcholine receptor. Genes 2013, 4(2):171-197. [http://www.mdpi.com/2073-4425/4/2/171/].
36. Ferretti M, Fabbiano C, Bari MD, Conte C, Castigli E, Sciaccaluga M, Ponti D, Ruggieri P, Raco A, Ricordy R, Calogero A, Tata AM. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells. J Cell Mol Med 2013, 17(4):552-566. [http://doi.wiley.com/10.1111/jcmm.12038].
37. Olsen SK. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Nat Acad Sci 2004, 101(4):935-940. [http://www.pnas.org/cgi/doi/10.1073/pnas.0307287101]. [PDB ID: 1RY7].
38. Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and Phosphatidylinositol 3-Kinase activation. Mol Biol Cell 2001, 12(4):931-942. [http://www.molbiolcell.org/cgi/doi/10.1091/mbc.12.4.931].
39. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Investig 2009, 119(5):1077-1079. [http://www.jci.org/articles/view/38948].
40. Rousseau F. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet 1996, 5(4):509-512. [http://www.hmg.oupjournals.org/cgi/doi/10.1093/hmg/5.4.509].
41. Hafner C. Mosaicism of activatingFGFR3 mutations in human skin causesepidermal nevi. J Clin Investig 2006, 116(8):2201-2207. [http://www.jci.org/cgi/doi/10.1172/JCI28163].
42. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Investig 2009, 119(5):1216-1229. [http://www.jci.org/articles/view/38017].
43. Gould AE, Adams R, Adhikari S, Aertgeerts K, Afroze R, Blackburn C, Calderwood EF, Chau R, Chouitar J, Duffey MO, England DB, Farrer C, Forsyth N, Garcia K, Gaulin J, Greenspan PD, Guo R, Harrison SJ, Huang SC, Iartchouk N, Janowick D, Kim MS, Kulkarni B, Langston SP, Liu JX, Ma LT, Menon S, Mizutani H, Paske E, Renou CC, et al. Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf i. J Med Chem 2011, 54(6):1836-1846. [http://pubs.acs.org/doi/abs/10.1021/jm101479y]. [PDB ID: 3Q96].
44. Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, Bandiera T, Fogliatto G, Bertrand JA. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010, 49(32):6813-6825. [http://pubs.acs.org/doi/abs/10.1021/bi1005514]. [PDB ID: 2XBA].
45. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R. Detection of BRAF V600E mutation by pyrosequencing. Pathology 2008, 40(3):295-298. [http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01268031-200840030-00009].
46. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954. [http://www.ncbi.nlm.nih.gov/pubmed/12068308]. [PMID: 12068308].
47. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418(6901):934. [http://www.ncbi.nlm.nih.gov/pubmed/12198537]. [PMID: 12198537].
48. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003, 63(17):5198-5202. [http://www.ncbi.nlm.nih.gov/pubmed/14500344]. [PMID: 14500344].
49. Andreu-Pérez P, Esteve-Puig R, de Torre-Minguela C, López-Fauqued M, Bech-Serra JJ, Tenbaum S, García-Trevijano ER, Canals F, Merlino G, Avila MA, Recio JA. Protein arginine methyltransferase 5 regulates ERK1/2, signal transduction amplitude and cell fate through CRAF. Sci Signal 2011, 4(190):ra58. [http://www.ncbi.nlm.nih.gov/pubmed/21917714]. [PMID: 21917714].
50. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YNV, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2012, 19(3):657-667. [http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-11-1446].
51. Lee JW, Yoo NJ, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Ko YH, Kim SH, Nam SW, Lee JY, Lee SH. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer 2003, 89(10):1958-1960. [http://www.ncbi.nlm.nih.gov/pubmed/14612909]. [PMID: 14612909].
52. Motegi A. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004, 117(15):3319-3329. [http://jcs.biologists.org/cgi/doi/10.1242/jcs.01183].
53. Bang YJ. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol & Lab Med 2012, 136(10):1201-1204. [PMID: 23020724].
54. George RE, Sanda T, Hanna M, Fröhling S, Ii WL, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455(7215):975-978. [http://www.nature.com/doifinder/10.1038/nature07397].
55. Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 2011, 30(17):2017-2025. [http://www.nature.com/doifinder/10.1038/onc.2010.595].
56. Sved J, Bird A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc Nat Acad Sci 1990, 87(12):4692-4696. [http://www.pnas.org/content/87/12/4692.abstract].
57. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science (New, York, N.Y.) 1991, 253(5015):49-53. [http://www.ncbi.nlm.nih.gov/pubmed/1905840]. [PMID: 1905840].